Silence Therapeutics Plc - ADR Stock

$4.54

4.82% yesterday

Nasdaq, Feb 28, 04:51 pm CET

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Silence Therapeutics Plc - ADR Stock price

$4.77

-14.73 75.54% 5Y

Nasdaq, Closing price Wed, Feb 26 2025

+0.08 1.71%

ISIN

US82686Q1013

Symbol

SLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$222.85m
Enterprise Value	$50.02m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	2.43
P/S ratio (TTM) P/S ratio	10.83
P/B ratio (TTM) P/B ratio	1.76
Revenue growth (TTM) Revenue growth	-40.10%
Revenue (TTM) Revenue	$20.57m
EBIT (operating result TTM) EBIT	$-74.19m
Free Cash Flow (TTM) Free Cash Flow	$-52.56m
Cash position	$173.02m
EPS (TTM) EPS	$-1.67
P/E forward	negative
P/S forward	9.14
EV/Sales forward	2.13
Short interest	4.33%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Silence Therapeutics Plc - ADR Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

5x Buy

83%

1x Sell

17%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

Buy

83%

Sell

17%

Analyst Estimates with Stock Price Targets

Financial data from Silence Therapeutics Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	21 21	40% 40% 100%
- Direct Costs	11 11	29% 29% 55%
Gross Profit	9.16 9.16	50% 50% 45%
- Selling and Administrative Expenses	25 25	6% 6% 122%
- Research and Development Expense	58 58	11% 11% 281%
EBITDA	-74 -74	28% 28% -358%
- Depreciation and Amortization	0.60 0.60	5% 5% 3%
EBIT (Operating Income) EBIT	-74 -74	28% 28% -361%
Net Profit	-75 -75	44% 44% -365%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Silence Therapeutics Plc - ADR Stock News

Neutral

Business Wire

●

one day ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. “2024 was marked by strong clinical execution and pipeline advancement, highl...

Neutral

Business Wire

●

15 days ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management wil...

Neutral

Business Wire

●

3 months ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented ...

More Silence Therapeutics Plc - ADR News

Company Profile

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Craig Tooman
Employees	109
Founded	1994
Website	www.silence-therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now